Brand Post | USA Newshour

Brand Post June 2, 2024

NVIDIA NIM Revolutionizes Model Deployment, Now Available to Transform World’s Millions of Developers Into Generative AI Developers

NVIDIA NIM NVIDIA NIM revolutionizes model deployment for every layer of the AI ecosystem. 150+ Partners Across Every Layer of…

Brand Post June 2, 2024

NVIDIA Releases Digital Human Microservices, Paving Way for Future of Generative AI Avatars

NVIDIA ACE Now Generally Available for Cloud, in Early Access for RTX AI PCs, in Use by Companies Across Customer…

Brand Post June 2, 2024

OncoHost Announces New Study on Biomarkers for Renal Cell Carcinoma

Kidney Cancer Research Aims to Enhance Metastatic Patient Management by Pinpointing Biomarker to Optimize Clinical Decision-Making BINYAMINA, Israel and CARY,…

Brand Post June 2, 2024

William Miller Spearheads Launch of Pioneering OkayCoin Staking Protocol

Los Angeles, CA, USA , June 02, 2024 (GLOBE NEWSWIRE) — Today, OkayCoin, a frontrunner in cryptocurrency staking solutions, marked a…

Brand Post June 2, 2024

CryptoHeap Launches Comprehensive Strategy for Crypto Staking Amidst Market Fluctuations

Miami, FL, June 02, 2024 (GLOBE NEWSWIRE) — In response to the ongoing volatility in the cryptocurrency markets, CryptoHeap, a…

Brand Post June 2, 2024

Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

Extended follow-up data reaching over two years in the earliest patients dosed reinforce the potential of NTLA-2002 to be a…

Brand Post June 2, 2024

Fast Guard Service Releases Guide to Choosing the Best Fire Watch Service

Top Fire watch organizations throughout the state of California SAN JOSE, Calif., June 2, 2024 /PRNewswire/ — Fast Guard Service,…

Brand Post June 2, 2024

Sunvozertinib’s Global Pivotal WU-KONG1B Study Meets Primary Endpoint in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

The global pivotal WU-KONG1B study investigating sunvozertinib achieved its primary objective with a manageable safety profile in relapsed or refractory…

Brand Post June 2, 2024

ePac Flexible Packaging Sets Strategy for Continued Double-Digit Growth

Technology focused company streamlines operations while focused on its digital platform Austin, Texas, June 02, 2024 (GLOBE NEWSWIRE) — ePac…

Brand Post June 2, 2024

Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting

SAN FRANCISCO and SUZHOU, China, June 2, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that…

Brand Post June 1, 2024

Live from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in Patients with NSCLC

SUZHOU, China, and ROCKVILLE, Md., June 1, 2024 /PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing…

Brand Post June 1, 2024

Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO

BEIJING and SHANGHAI and CHICAGO, June 1, 2024 /PRNewswire/ — Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable…

Brand Post June 1, 2024

CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC

EMA CHMP recommendation is based on the results of a Phase 3 clinical trial (GEMSTONE-302) demonstrating significant progression-free survival (PFS)…

Brand Post June 1, 2024

Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting

SAN FRANCISCO, U.S. and SUZHOU, China, June 1, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical…

Brand Post June 1, 2024

Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting

SAN FRANCISCO, U.S. and SUZHOU, China, June 1, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical…